Novel Cancer Vaccine Fails to Improve Overall Survival in Lung Cancer Clinical Trial | Lung Cancer Dispatch |

A phase III clinical trial investigating the novel cancer vaccine L-BLP25 (Stimuvax) found that it produced no significant improvement in overall patient survival. However, the drug did show promising results in certain subgroups of patients. The trial investigators therefore plan to conduct more detailed analyses of the trial data and will also move ahead with another phase III clinical trial testing the drug in a different patient population.

Primary source: